RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Minerva Neurosciences Stocks 2024

Minerva Neurosciences Stocks

6.51 M

Minerva Neurosciences Dividend yield

Ticker

NERV

ISIN

US6033801068

WKN

A1171S

In 2024, Minerva Neurosciences had 6.51 M outstanding stocks, a 0% change from the 6.51 M stocks in the previous year.

The Minerva Neurosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e6.51
2028e6.51
2027e6.51
2026e6.51
2025e6.51
2024e6.51
20236.51
20225.34
20215.34
20205.11
20194.88
20184.85
20174.74
20163.94
20152.93
20141.59
20132.28
20122.28
20112.28

Minerva Neurosciences Aktienanalyse

What does Minerva Neurosciences do?

Minerva Neurosciences was founded in 2007 and is a biopharmaceutical company focused on developing therapies for various psychiatric and neurological disorders. The company's business model is based on identifying promising molecules and developing them clinically until they are approved by health authorities. Minerva works closely with academic institutions and other partners to expand its pipeline of potential products. The company is focused on developing therapies for disorders such as schizophrenia, depression, sleep disorders, Parkinson's, and Alzheimer's. Minerva Neurosciences' main products are the antipsychotic MIN-101, targeting the treatment of schizophrenia, and the antidepressant MIN-117, developed for the treatment of depression. Both products are currently in clinical development and have the potential to offer new treatment options for patients. Furthermore, Minerva Neurosciences has entered into exclusive licensing agreements with other companies to develop innovative therapies for rare diseases. One of these products is the medication Roluperidone, which can be used for schizophrenic disorders. Minerva Neurosciences is divided into three business segments: Minerva Neurosciences Inc, Minerva Manufacturing Inc, and Minerva Therapeutics Inc. Minerva Manufacturing has its own research and development department and specializes in manufacturing clinical trial products. Minerva Therapeutics is a subsidiary focused on developing gene therapies for rare diseases. The company aims to improve the quality of life for patients with neurological and psychiatric disorders. Minerva Neurosciences pursues a strategy of collaborating with external partners and academic institutions to foster innovation and develop new therapies. Overall, Minerva Neurosciences has the potential to play a significant role in the treatment of central nervous system disorders and improve the health and well-being of millions of people worldwide. Minerva Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Minerva Neurosciences's Shares Outstanding

Minerva Neurosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Minerva Neurosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Minerva Neurosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Minerva Neurosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Minerva Neurosciences Stock

How many stocks are there of Minerva Neurosciences?

The current number of stocks of Minerva Neurosciences is 6.51 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Minerva Neurosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Minerva Neurosciences evolved in recent years?

The number of shares of Minerva Neurosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Minerva Neurosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Minerva Neurosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Minerva Neurosciences pay?

Over the past 12 months, Minerva Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Minerva Neurosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Minerva Neurosciences?

The current dividend yield of Minerva Neurosciences is .

When does Minerva Neurosciences pay dividends?

Minerva Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Minerva Neurosciences?

Minerva Neurosciences paid dividends every year for the past 0 years.

What is the dividend of Minerva Neurosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Minerva Neurosciences located?

Minerva Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Minerva Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Minerva Neurosciences from 6/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Minerva Neurosciences pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Minerva Neurosciences in the year 2023?

In the year 2023, Minerva Neurosciences distributed 0 USD as dividends.

In which currency does Minerva Neurosciences pay out the dividend?

The dividends of Minerva Neurosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Minerva Neurosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Minerva Neurosciences

Our stock analysis for Minerva Neurosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Minerva Neurosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.